Search Results

Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of dollars into the industry.

Blackstone (NYSE:BX) today announced the launch of the Blackstone Life Sciences (“Blackstone”) portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation.

Blackstone announced a new collaboration with Moderna, Inc. through a development and commercialization funding agreement where funds managed by Blackstone Life Sciences will provide up to $750 million to fund Moderna’s influenza program.

Armed with a $300 million commitment from Blackstone Life Sciences and a former Merck monoclonal antibody, Uniquity Bio is starting Phase II clinical trials in asthma and chronic obstructive pulmonary disease.

Amicus Therapeutics today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackstone Life Sciences and Blackstone Credit have agreed to provide Amicus with a $400 million senior secured term loan facilitating a refinancing of existing debt and a $30 million strategic investment in Amicus’s common stock.

Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.